

chain nodes :

29 30 31 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 21 22 23 24 25 26

chain bonds :

16-29 16-31 21-34 24-31 29-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-14 6-16 7-8 7-12 8-9 8-16 9-10 9-15 10-11 11-12  
14-15 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :

5-14 6-16 8-16 9-15 14-15 16-29 16-31 21-22 21-26 21-34 22-23 23-24 24-25  
24-31 25-26 29-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:C,O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 14:Atom 15:Atom 16:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom  
29:CLASS 30:CLASS 31:CLASS 34:Atom

10/089024

=> s 11

SAMPLE SEARCH INITIATED 17:44:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1471 TO ITERATE

68.0% PROCESSED 1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

9 ANSWERS



FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 27120 TO 31720  
PROJECTED ANSWERS: 46 TO 482

L2 9 SEA SSS SAM L1

=> d 12 1-9

10/089024

L2 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 348134-75-8 REGISTRY  
CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C33 H33 F3 N4 O2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/089024

L2 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 348134-10-1 REGISTRY  
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C32 H33 F3 N4 O S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/089024

L2 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 348134-08-7 REGISTRY  
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-chloro-2-benzothiazolyl)hexahydro-1H-  
1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C32 H32 Cl F3 N4 O S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/089024

L2 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 348133-87-9 REGISTRY  
CN 9H-Fluorene-9-carboxamide, 9-[4-[3-methyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C34 H35 F3 N4 O  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/089024

L2 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 348133-53-9 REGISTRY  
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-methoxy-1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C33 H36 F3 N5 O2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/089024

L2 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 348133-30-2 REGISTRY  
CN 9H-Fluorene-9-carboxamide, N-(phenylmethyl)-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C38 H38 N4 O  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)




10/089024

L2 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 301668-32-6 REGISTRY  
CN Benzoic acid, 3-[4-[3-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C32 H34 F3 N3 O3  
SR CA  
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


10/089024

L2 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 301668-00-8 REGISTRY  
CN Benzoic acid, 4-[4-[3-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C32 H34 F3 N3 O3  
SR CA  
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


10/089024

L2 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 301667-21-0 REGISTRY  
CN 5H-Dibenzo[a,d]cycloheptene-5-carboxamide, 5-[4-[4-(2-cyclohexyl-2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazinyl]butyl]-10,11-dihydro-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C40 H47 F3 N4 O2  
SR CA  
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/089024

=> s l1 sss full

FULL SEARCH INITIATED 17:45:21 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 28971 TO ITERATE

100.0% PROCESSED 28971 ITERATIONS  
SEARCH TIME: 00.00.01

247 ANSWERS

L3 247 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
163.67	163.88

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:45:32 ON 02 OCT 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2003 VOL 139 ISS 14  
FILE LAST UPDATED: 1 Oct 2003 (20031001/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s l3

L4 4 L3

=> d l4 1-4 bib abs hitstr



L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2001:489378 CAPLUS  
 DN 135:92650  
 TI Preparation of 9-piperazinoalkyl-9H-fluorene-9-carboxamides as inhibitors of microsomal triglyceride transfer protein (MTP)  
 IN Lehmann-Lintz, Thorsten; Heckel, Armin; Thomas, Leo; Mark, Michael  
 PA Boehringer Ingelheim Pharma K.-G., Germany  
 SO PCT Int. Appl., 122 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047898	A2	20010705	WO 2000-EP12843	20001216
	WO 2001047898	A3	20020404		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	DE 19963234	A1	20020124	DE 1999-19963234	19991227
	EP 1255736	A2	20021113	EP 2000-991607	20001216
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2003521484	T2	20030715	JP 2001-549370	20001216
	US 2003166637	A1	20030904	US 2002-168486	20021009
PRAI	DE 1999-19963234	A	19991227		
	WO 2000-EP12843	W	20001216		
OS	MARPAT 135:92650				
GI					



AB Title compds. [I; R1 = (substituted) (polycyclic) aryl, heteroaryl; R2, R3 = H, alkyl; R5, R6 = H, (substituted) alkyl, cycloalkyl, Ph, alkoxy carbonylalkyl, carboxyalkyl, etc.; R5R6N = cycloalkylenimino; X = bond, O, CH2, CH2CH2, (substituted) imino; X1 = (CH2)m; X2 = (CH2)n; m = 2,3; n = 1-5] were prep'd. as MTP inhibitors (no data). Thus, 9-(4-bromobutyl)-9H-fluorene-9-(2,2,2-trifluoroethyl)carboxamide (prepn. given) was stirred for 10 h at room temp. with 2-(piperazin-1-yl)benzothiazole, K2CO3 and H2O in MeCN to give 60.4% 9-[4-(4-benzothiazol-

2-yl)-piperazin-1-ylbutyl]-9H-fluoren-9-(2,2,2-trifluoroethyl)carboxamide.  
 IT **348133-66-4P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of piperazinoalkylfluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein (MTP))  
 RN 348133-66-4 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(8-methoxy-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



IT 348133-25-5P 348133-26-6P 348133-27-7P  
 348133-28-8P 348133-30-2P 348133-31-3P  
 348133-32-4P 348133-34-6P 348133-36-8P  
 348133-37-9P 348133-38-0P 348133-39-1P  
 348133-41-5P 348133-42-6P 348133-44-8P  
 348133-49-3P 348133-51-7P 348133-53-9P  
 348133-55-1P 348133-56-2P 348133-57-3P  
 348133-59-5P 348133-60-8P 348133-61-9P  
 348133-62-0P 348133-63-1P 348133-64-2P  
 348133-67-5P 348133-68-6P 348133-71-1P  
 348133-72-2P 348133-73-3P 348133-75-5P  
 348133-77-7P 348133-82-4P 348133-84-6P  
 348133-87-9P 348133-88-0P 348133-90-4P  
 348133-92-6P 348133-94-8P 348133-96-0P  
 348133-98-2P 348134-00-9P 348134-02-1P  
 348134-04-3P 348134-06-5P 348134-08-7P  
 348134-10-1P 348134-11-2P 348134-12-3P  
 348134-13-4P 348134-14-5P 348134-15-6P  
 348134-16-7P 348134-17-8P 348134-18-9P  
 348134-19-0P 348134-20-3P 348134-21-4P  
 348134-22-5P 348134-23-6P 348134-24-7P



348134-25-8P 348134-26-9P 348134-27-0P  
 348134-28-1P 348134-29-2P 348134-30-5P  
 348134-31-6P 348134-32-7P 348134-33-8P  
 348134-34-9P 348134-35-0P 348134-36-1P  
 348134-38-3P 348134-40-7P 348134-42-9P  
 348134-44-1P 348134-46-3P 348134-48-5P  
 348134-50-9P 348134-51-0P 348134-53-2P  
 348134-55-4P 348134-57-6P 348134-58-7P  
 348134-60-1P 348134-62-3P 348134-64-5P  
 348134-66-7P 348134-67-8P 348134-68-9P  
 348134-69-0P 348134-70-3P 348134-73-6P  
 348134-74-7P 348134-75-8P 348134-76-9P  
 348134-77-0P 348134-78-1P 348134-79-2P  
 348134-80-5P 348134-81-6P 348134-82-7P  
 348134-83-8P 348134-84-9P 348134-85-0P  
 348134-86-1P 348134-88-3P 348134-89-4P  
 348134-90-7P 348134-91-8P 348134-93-0P  
 348134-95-2P 348134-97-4P 348134-98-5P  
 348134-99-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperazinoalkylfluorenecarboxamides as inhibitors of microsomal triglyceride transfer protein (MTP))



RN 348133-25-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348133-26-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzoxazolyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-27-7 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-28-8 CAPLUS



CN 9H-Fluorene-9-carboxamide, N-propyl-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)







RN 348133-30-2 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-(phenylmethyl)-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)





RN 348133-31-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-ethyl-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)





RN 348133-32-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-cyclopentyl-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)





RN 348133-34-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-phenyl-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 348133-36-8 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-quinazolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 348133-37-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348133-38-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(1-ethyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348133-39-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1-(1-methylethyl)-1H-benzimidazol-2-yl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348133-41-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1-(phenylmethyl)-1H-benzimidazol-2-yl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348133-42-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(1-phenyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 348133-44-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-fluoro-1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-49-3 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-51-7 CAPLUS


10/089024

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(5-chloro-1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-53-9 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-methoxy-1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-55-1 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348133-56-2 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-quinoxalinyloxy)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 348133-57-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(5-chloro-2-quinoxalinyloxy)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 348133-59-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-chloro-2-benzothiazolyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




10/089024


RN 348133-60-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-phenyl-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 348133-61-9 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(7-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 348133-62-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(5-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



10/089024



RN 348133-63-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-64-2 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(8-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



10/089024



RN 348133-67-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(8-hydroxy-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-68-6 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(8-bromo-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



10/089024


RN 348133-71-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(8-phenyl-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348133-72-2 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-methyl-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348133-73-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(3-methyl-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-75-5 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(1-methoxy-3-isoquinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-77-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(8-ethoxy-2-naphthalenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)






RN 348133-82-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2S)-2-methyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348133-84-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R)-2-methyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



10/089024

RN 348133-87-9 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[3-methyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348133-88-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,5S)-2,5-dimethyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348133-90-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-2,6-dimethyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348133-92-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-2,6-dimethyl-4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348133-94-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-4-(5-chloro-2-quinolinyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 348133-96-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-4-(2-benzothiazolyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)

10/089024


Relative stereochemistry.



RN 348133-98-2 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-4-(2-benzoxazolyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348134-00-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-2,6-dimethyl-4-(2-quinazolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 348134-02-1 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[hexahydro-4-(2-quinazolinyl)-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

10/089024





RN 348134-04-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[hexahydro-4-(2-quinolinyl)-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348134-06-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-chloro-2-quinolinyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348134-08-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-chloro-2-benzothiazolyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348134-10-1 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 348134-11-2 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 348134-12-3 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(5-chloro-2-quinolinyl)-1-

piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348134-13-4 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(8-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 348134-14-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[4-(2-quinoxaliny)-1-piperaziny]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348134-15-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[4-(2-quinazolinyl)-1-piperaziny]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 348134-16-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)-1-piperazinyl]butyl]-  
N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




10/089024


RN 348134-17-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348134-18-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(1-ethyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 348134-19-0 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-fluoro-1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 348134-20-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[(2S)-2-methyl-4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348134-21-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-2,6-dimethyl-4-(2-quinolinyl)-1-

10/089024

piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348134-22-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-4-(5-chloro-2-quinolinyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348134-23-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-2,6-dimethyl-4-(2-quinazolinyl)-1-piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348134-24-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-2,6-dimethyl-4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348134-25-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-4-(2-benzoxazolyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 348134-26-9 CAPLUS

10/089024



CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-4-(2-benzothiazolyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-[(4-fluorophenyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 348134-27-0 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 348134-28-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-methoxyphenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348134-29-2 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(5-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 348134-30-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-methoxyphenyl)methyl]-9-[4-[4-(2-quinazolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348134-31-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-methoxyphenyl)methyl]-9-[4-[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 348134-32-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)-1-piperazinyl]butyl]-  
N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




10/089024

RN 348134-33-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-2,6-dimethyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-[(4-methoxyphenyl)methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348134-34-9 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[(2R,6S)-4-(5-chloro-2-quinolinyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-[(4-methoxyphenyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 348134-35-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 348134-36-1 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, N-[(2-methoxyphenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 348134-38-3 CAPLUS

10/089024


CN 9H-Fluorene-9-carboxamide, N-[(3-methoxyphenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 348134-40-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(2,4-dimethoxyphenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348134-42-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348134-44-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 348134-46-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(3,4-difluorophenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



PAGE 1-A





RN 348134-48-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2,3,3,3-pentafluoropropyl)-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 348134-50-9 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,3,3,3-pentafluoropropyl)- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A



RN 348134-51-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-(4-pyridinylmethyl)-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)




10/089024


RN 348134-53-2 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2-pyridinylmethyl)-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 348134-55-4 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 348134-57-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-propyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



10/089024



RN 348134-58-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2-phenylethyl)-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 348134-60-1 CAPLUS



CN 9H-Fluorene-9-carboxamide, N-(3-methoxypropyl)-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



10/089024



RN 348134-62-3 CAPLUS

CN .beta.-Alanine, N-[[9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-9H-fluoren-9-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 348134-64-5 CAPLUS



CN Glycine, N-[[9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-9H-fluoren-9-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



10/089024



RN 348134-66-7 CAPLUS

CN .beta.-Alanine, N-[[9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-9H-fluoren-9-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 348134-67-8 CAPLUS

CN Glycine, N-[[9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-9H-fluoren-9-yl]carbonyl]- (9CI) (CA INDEX NAME)




10/089024

RN 348134-68-9 CAPLUS



CN 9H-Fluorene-9-carboxamide, N-[(3,4-difluorophenyl)methyl]-9-[4-[(2R,6S)-2,6-dimethyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 348134-69-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-propyl- (9CI) (CA INDEX NAME)





RN 348134-70-3 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348134-73-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(2-benzoxazolyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 348134-74-7 CAPLUS


CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A



RN 348134-75-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




10/089024


RN 348134-76-9 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(5-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 348134-77-0 CAPLUS



CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(6-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348134-78-1 CAPLUS  
 CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(8-chloro-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348134-79-2 CAPLUS  
 CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(8-methoxy-2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348134-80-5 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(2-quinoxaliny)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 348134-81-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[(2S)-2-methyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

10/089024


Absolute stereochemistry.



RN 348134-82-7 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[(2R,6S)-4-(2-benzothiazolyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348134-83-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[(2R,6S)-2,6-dimethyl-4-(2-quinolinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348134-84-9 CAPLUS



CN 9H-Xanthene-9-carboxamide, 9-[4-[(2R,6S)-4-(5-chloro-2-quinolinyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 348134-85-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(2-benzothiazolyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348134-86-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[hexahydro-4-(1-methyl-1H-benzimidazol-2-yl)-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348134-88-3 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[hexahydro-4-(1-methyl-1H-benzimidazol-2-yl)-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 348134-89-4 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[hexahydro-4-(2-quinolinyl)-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348134-90-7 CAPLUS



CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(6-chloro-2-quinolinyl)hexahydro-1H-1,4-diazepin-1-yl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348134-91-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-butyl-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)







RN 348134-93-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



10/089024



RN 348134-95-2 CAPLUS

CN Morpholine, 4-[[9-[4-[4-(2-quinolinyl)-1-piperazinyl]butyl]-9H-xanthen-9-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 348134-97-4 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[3-[4-(2-quinolinyl)-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



10/089024



RN 348134-98-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[3-[4-(2-benzothiazolyl)-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 348134-99-6 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[3-[hexahydro-4-(2-quinolinyl)-1H-1,4-diazepin-1-yl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



10/089024

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2001:228874 CAPLUS  
DN 134:266313  
TI Preparation and use of substituted piperazine derivatives as MTP  
inhibitors  
IN Lehmann-Lintz, Thorsten; Heckel, Armin; Thomas, Leo; Mark, Michael  
PA Boehringer Ingelheim Pharma K.-G., Germany  
SO PCT Int. Appl., 70 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021604	A1	20010329	WO 2000-EP9146	20000919
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 19945594	A1	20010329	DE 1999-19945594	19990923
	EP 1228053	A1	20020807	EP 2000-969264	20000919
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003509505	T2	20030311	JP 2001-524983	20000919
PRAI	DE 1999-19945594	A	19990923		
	WO 2000-EP9146	W	20000919		
OS	MARPAT 134:266313				
GI					



AB Compds. of formula I [wherein; n is 1-5; m is 1 or 2; X is a bond, O, CH<sub>2</sub>(CH<sub>2</sub>), imino or N-alkyl-imino; R<sub>1</sub> is (substituted) aryl or heteroaryl; R<sub>2</sub>, R<sub>3</sub> are hydrogen or alkyl; R<sub>6</sub>, R<sub>7</sub> are H, (fluoro)alkyl, cycloalkyl, Ph, heteroaryl, etc., or NR<sub>6</sub>R<sub>7</sub> may form a 3-7 membered ring.]. Thirty eight examples of I are prepd. (e.g. II). Compd. II was prepd. by alkylation of 9-fluorencarboxylic acid with 1,4-dibromobutane. The alkylated intermediate was converted to its acyl chloride deriv., and treated with 2,2,2-trifluoroethylamine to provide pivotal intermediate, 9-(4-bromobutyl)-9H-fluorene-9-(2,2,2-trifluoroethylcarboxamide). Alkylation of 1-phenylpiperazine with this intermediate yields II. Three solid oral dosage formulations of compds. I are disclosed. Compds. of formula I are said to be inhibitors of the microsomal triglyceride-transfer protein (MTP). Use of compds. I to prep. drugs which lower plasma levels of atherogenic lipoproteins is claimed.


IT **331767-31-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. and use of substituted piperazine derivs.)


RN 331767-31-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-nitrophenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





IT 331767-10-3P 331767-12-5P 331767-14-7P  
 331767-15-8P 331767-16-9P 331767-18-1P  
 331767-19-2P 331767-20-5P 331767-22-7P  
 331767-24-9P 331767-25-0P 331767-26-1P  
 331767-27-2P 331767-28-3P 331767-29-4P  
 331767-30-7P 331767-32-9P 331767-33-0P  
 331767-34-1P 331767-35-2P 331767-36-3P  
 331767-37-4P 331767-38-5P 331767-39-6P  
 331767-40-9P 331767-41-0P 331767-42-1P  
 331767-43-2P 331767-44-3P 331767-45-4P  
 331767-46-5P 331767-47-6P 331767-48-7P  
 331767-49-8P 331767-50-1P 331767-51-2P  
 331767-52-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. and use of substituted piperazine derivs.)

RN 331767-10-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-(4-phenyl-1-piperazinyl)butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 331767-12-5 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[4-(4-[1,1'-biphenyl]-3-yl-1-piperazinyl)butyl]-N-(2,2,2-trifluoroethyl)-, compd. with benzene (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 331767-11-4

CMF C36 H36 F3 N3 O

PAGE 1-A





CM 2

CRN 71-43-2

CMF C6 H6




RN 331767-14-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-(4-[1,1'-biphenyl]-4-yl-1-piperazinyl)butyl]-N-(2,2,2-trifluoroethyl)-, compd. with benzene (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 331767-13-6

CMF C36 H36 F3 N3 O





PAGE 2-A



CM 2

CRN 71-43-2


CMF C6 H6




RN 331767-15-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-chlorophenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-16-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(3-chlorophenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-18-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-(phenylmethoxy)phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-19-2 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-20-5 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-22-7 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-fluorophenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-24-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-25-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[3-methyl-4-(4-methylphenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-26-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(3,4-dichlorophenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-27-2 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-methoxyphenyl)-1-piperazinyl]butyl]-  
 N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-28-3 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-  
 N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-29-4 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2,4-dimethoxyphenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 331767-30-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-32-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-aminophenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl


RN 331767-33-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-methylphenyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-34-1 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-pyridinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-35-2 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-methoxy-2-pyridinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-36-3 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[4-(6-methoxy-2-pyridinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-37-4 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, N-[(4-methoxyphenyl)methyl]-9-[4-[4-(6-methoxy-2-pyridinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-38-5 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-ethoxy-2-pyridinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-39-6 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-40-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[4-(6-methyl-2-pyridinyl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-41-0 CAPLUS  
CN 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-42-1 CAPLUS  
CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-phenyl-2-pyridinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 331767-43-2 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(4-phenyl-2-pyridinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-44-3 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-phenoxy-2-pyridinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-45-4 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[6-(4-chlorophenoxy)-2-pyridinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-46-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[6-(3-chlorophenoxy)-2-pyridinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-47-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[6-(2-chlorophenoxy)-2-pyridinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-48-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[6-(4-methoxyphenoxy)-2-pyridinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-49-8 CAPLUS  
 CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(6-methoxy-2-pyridinyl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-50-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(6-methoxy-2-pyridinyl)-2,6-dimethyl-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-51-2 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-[(4-fluorophenyl)methyl]-9-[4-[4-(6-methoxy-2-pyridinyl)-2,6-dimethyl-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 331767-52-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(3-phenyl-1,2,4-thiadiazol-5-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT





10/089024

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2000:742072 CAPLUS  
 DN 133:309907  
 TI Preparation of nitrogen-containing heterocyclic compounds and benzamide compounds as hypolipidemics and antiarteriosclerotics  
 IN Ohkura, Naoto; Hiraiwa, Yukiko; Matsushima, Tetsuya; Sasaki, Kazue; Yamamoto, Takehiro; Shiotani, Masaharu; Suzuki, Shigeki; Nakatani, Yuuko; Kuroda, Chizuko; Nagasawa, Mieko; Katano, Kiyoaki  
 PA Meiji Seika Kaisha, Ltd., Japan  
 SO PCT Int. Appl., 284 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

nothing  
on 3110"


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061556	A1	20001019	WO 2000-JP2329	20000410
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000036759	A5	20001114	AU 2000-36759	20000410
	BR 2000009650	A	20020102	BR 2000-9650	20000410
	EP 1180514	A1	20020220	EP 2000-915465	20000410
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	JP 1999-102559	A	19990409		
	JP 1999-118490	A	19990426		
	JP 1999-119043	A	19990427		
	WO 2000-JP2329	W	20000410		
OS	MARPAT 133:309907				
GI					





II

- AB The title compds. [I; R1 and R2 represent each (un)substituted C1-6 alkyl or alkoxy, C3-8 cycloalkyl, Ph, C2-6 alkenyl or alkynyl, 5- or 6-membered ring (un)satd. heterocyclyl; R3 and R4 represent each hydrogen, (un)substituted C1-6 alkyl, halo, OH, cyano, C2-5 alkoxy carbonyl, C1-6 alkoxy, or CO<sub>2</sub>H ; or R2 and R3 may be bonded to each other to form (CH<sub>2</sub>)<sub>m</sub>, N:CH, CH:N, or (C1-6 alkyl)-C:N; wherein m is 1 or 2; A, D, E and G represent each C, or one of A, D, E and G represents N and the remainders represent C; Q represents N or C; Y represents a group represented by general formula Q1 (wherein X represents hydrogen, CONR<sup>5</sup>R<sup>6</sup>, etc.; R<sup>8</sup> represents nil or a bond, O, etc.; and R<sup>9</sup> and R<sup>10</sup> represent each hydrogen, alkyl, etc.); and Z represents (CH<sub>2</sub>)<sub>n</sub>, O(CH<sub>2</sub>)<sub>i</sub>, or CONH(CH<sub>2</sub>)<sub>i</sub>; wherein n is 0-6; i is 1-6] are prepd. These compds. have an effect of inhibiting the biosynthesis of triglycerides in the liver and an effect of inhibiting the secretion of apolipoprotein B-contg. lipoproteins from the liver (the latter effect being particularly excellent), without showing the side effect of fat accumulation in the liver, and are useful in treating and preventing hyperlipemia, arteriosclerotic diseases, and pancreatitis. Thus, to a soln. of 2-benzyl-7-[4-[4-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluoren-9-yl]butyl]piperazin-1-yl]-3,4-dihydro-2H-isoquinolin-1-one in PhMe were added NaOH, K<sub>2</sub>CO<sub>3</sub>, tetrabutylammonium hydrogen sulfate, and allyl bromide and the resulting mixt. was stirred at 60.degree. overnight to give title compd. (II). II in vitro inhibited the secretion of apolipoprotein B by 89% and the biosynthesis of triglycerides by 89% in HepG2 cells. Tablet and capsule formulations were also described.
- IT **301667-09-4P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of)
- RN 301667-09-4 CAPLUS
- CN 3-Pyridinecarboxamide, N-cyclohexyl-N-(2-pyridinylmethyl)-6-[4-[4-[9-[[2,2,2-trifluoroethyl]amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT    301666-32-0P   301666-35-3P   301666-36-4P  
       301666-38-6P   301666-46-6P   301666-47-7P  
       301666-48-8P   301666-50-2P   301666-52-4P  
       301666-53-5P   301666-54-6P   301666-57-9P  
       301666-58-0P   301666-59-1P   301666-97-7P  
       301667-02-7P   301667-08-3P   301667-10-7P  
       301667-12-9P   301667-14-1P   301667-16-3P  
       301667-18-5P   301667-19-6P   301667-20-9P  
       301667-21-0P   301667-25-4P   301667-28-7P  
       301667-29-8P   301667-33-4P   301667-37-8P  
       301667-39-0P   301667-40-3P   301667-50-5P  
       301667-58-3P   301667-61-8P   301667-62-9P  
       301667-63-0P   301667-64-1P   301667-68-5P

301667-69-6P 301667-77-6P 301667-79-8P  
 301667-99-2P 301668-01-9P 301668-03-1P  
 301668-06-4P 301668-08-6P 301668-09-7P  
 301668-12-2P 301668-14-4P 301668-18-8P  
 301668-23-5P 301668-24-6P 301668-25-7P  
 301668-26-8P 301668-31-5P 301668-48-4P  
 301668-49-5P 301668-52-0P 301668-54-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nitrogen-contg. heterocyclic compds. and benzamide compds. as hypolipidemics and antiarteriosclerotics and inhibitors of apolipoprotein B-contg. lipoproteins and biosynthesis of triglycerides)


RN 301666-32-0 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[3-[(cyclohexyl-2-propenylamino)carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301666-35-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[3-[[cyclohexyl(phenylmethyl)amino]carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301666-36-4 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[(cyclohexyl-2-propenylamino)carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301666-38-6 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[(cyclohexyl-2-propenylamino)carbonyl]-2-fluorophenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301666-46-6 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 301666-47-7 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[3-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME).

PAGE 1-A






PAGE 2-A




RN 301666-48-8 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[5-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]pentyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301666-50-2 CAPLUS  
 CN 9H-Xanthene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 301666-52-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301666-53-5 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(phenylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301666-54-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, N-(2,2-dimethylpropyl)-9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(tetrahydro-2H-pyran-2-yl)-7-isoquinolinyl]-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



RN 301666-57-9 CAPLUS



CN 9H-Fluorene-9-carboxamide, N-(2,2-dimethylpropyl)-9-[3-[4-[1,2,3,4-tetrahydro-1-oxo-2-(tetrahydro-2H-pyran-2-yl)-7-isoquinolinyl]-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 301666-58-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-(2,2-dimethylpropyl)-9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(tetrahydro-2H-pyran-2-yl)-7-isoquinolinyl]-1-



piperazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 301666-59-1 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-2-propenyl-9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(tetrahydro-2H-pyran-2-yl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301666-97-7 CAPLUS  
 CN 4-Pyridinecarboxamide, N-cyclohexyl-2-methyl-N-2-propenyl-3-[4-[3-[9-  
 [(2,2,2-trifluoroethyl)amino]carbonyl]-9H-xanthen-9-yl]propyl]-1-  
 piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301667-02-7 CAPLUS  
 CN 3-Pyridinecarboxamide, N-cyclohexyl-N-2-propenyl-6-[4-[4-[9-[(2,2,2-  
 trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-  
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301667-08-3 CAPLUS

CN 3-Pyridinecarboxamide, N-cyclohexyl-N-propyl-6-[4-[4-[9-[[ (2,2,2-trifluoroethyl) amino] carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301667-10-7 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 301667-12-9 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-N-ethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301667-14-1 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301667-16-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-N-2-propenyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301667-18-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-N-2-propenyl-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301667-19-6 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-N-(phenylmethyl)-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 301667-20-9 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-N-methyl-N-(2,2,2-trifluoroethyl)-


10/089024

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301667-21-0 CAPLUS

CN 5H-Dibenzo[a,d]cycloheptene-5-carboxamide, 5-[4-[4-(2-cyclohexyl-2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazinyl]butyl]-10,11-dihydro-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A







RN 301667-25-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[1,2,3,4-tetrahydro-1-oxo-2-(2-pyridinylmethyl)-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 301667-28-7 CAPLUS


CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[1,2,3,4-tetrahydro-1-oxo-2-(2-pyridinylmethyl)-7-isoquinolinyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 301667-29-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[2-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]ethyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301667-33-4 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[8-chloro-1,2,3,4-tetrahydro-2-[(3-methoxyphenyl)methyl]-1-oxo-7-isoquinolinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301667-37-8 CAPLUS  
 CN 9H-Fluorene-9-carboxylic acid, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]-, ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A





RN 301667-39-0 CAPLUS

CN 9H-Fluorene-9-carboxylic acid, 9-[4-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]butyl]- (9CI) (CA INDEX NAME)





RN 301667-40-3 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[3-[4-(2-cyclohexyl-2,3-dihydro-1-oxo-1H-isoindol-5-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 301667-50-5 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[2,3-dihydro-3-oxo-2-(phenylmethyl)-1H-isoindol-5-yl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 301667-58-3 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[3,4-dihydro-4-oxo-3-(phenylmethyl)-6-

phthalazinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA  
INDEX NAME)



RN 301667-61-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-[3,4-dihydro-4-oxo-3-(phenylmethyl)-6-phthalazinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA  
INDEX NAME)





RN 301667-62-9 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[3,4-dihydro-4-oxo-3-(phenylmethyl)-6-



10/089024

phthalazinyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA  
INDEX NAME)



RN 301667-63-0 CAPLUS



CN 9H-Xanthene-9-carboxamide, 9-[3-[4-[3,4-dihydro-4-oxo-3-(phenylmethyl)-6-phthalazinyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA  
INDEX NAME)



RN 301667-64-1 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[3,4-dihydro-4-oxo-3-(tetrahydro-2H-

pyran-2-yl)-6-phthalazinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)-  
(9CI) (CA INDEX NAME)



RN 301667-68-5 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[4-[4-[3,4-dihydro-4-oxo-3-[(tetrahydro-2H-pyran-2-yl)methyl]-6-phthalazinyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301667-69-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[3,4-dihydro-4-oxo-3-(2-



10/089024

pyridinylmethyl)-6-phthalazinyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 301667-77-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[3-[4-[3,4-dihydro-4-oxo-3-(2-pyridinylmethyl)-6-phthalazinyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301667-79-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[3-[4-[3,4-dihydro-4-oxo-3-(3-

10/089024


pyridinylmethyl)-6-phthalazinyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)





RN 301667-99-2 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[4-[(cyclohexyl-2-propenylamino) carbonyl]phenyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 301668-01-9 CAPLUS



CN 9H-Xanthene-9-carboxamide, 9-[4-[4-[4-[(cyclohexyl-2-propenylamino) carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A





RN 301668-03-1 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[3-chloro-4-[(cyclohexyl-2-propenylamino)carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301668-06-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[[cyclohexyl(phenylmethyl)amino]carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-08-6 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[(1-methylethyl)(phenylmethyl)amino]carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-09-7 CAPLUS

CN 9H-Xanthene-9-carboxamide, 9-[3-[4-[3-[(cyclohexyl-2-propenylamino)carbonyl]-2-methylphenyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301668-12-2 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[5-[4-[4-[(cyclohexyl-2-propenylamino) carbonyl]phenyl]-1-piperazinyl]pentyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301668-14-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[(cyclohexyl-2-propenylamino) carbonyl]-3-(trifluoromethyl)phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301668-18-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[(cyclohexyl-2-propenylamino)carbonyl]-3-fluorophenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301668-23-5 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[[cyclohexyl(2-pyridinylmethyl)amino]carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 301668-24-6 CAPLUS



CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[[cyclohexyl(2-furanylmethyl)amino]carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A





RN 301668-25-7 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[[cyclohexyl(2-thienylmethyl)amino]carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-26-8 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[3-[(cyclohexyl-2-propenylamino) carbonyl]-4-methylphenyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-31-5 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[3-[(cyclohexyl-2-propenyl)amino]carbonyl]phenyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301668-48-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[3-[(cyclohexyl-2-propenylamino)carbonyl]phenyl]-1-piperazinyl]butyl]-N-2-propenyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-49-5 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[3-[(cyclohexyl-2-propenylamino)carbonyl]-2-methylphenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-52-0 CAPLUS  
 CN 9H-Xanthene-9-carboxamide, 9-[4-[4-[3-[(cyclohexyl-2-propenylamino) carbonyl]-2-methylphenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-54-2 CAPLUS  
 CN 9H-Fluorene-9-carboxamide, 9-[3-[4-[3-[(cyclohexyl-2-propenylamino)carbonyl]-2-methylphenyl]-1-piperazinyl]propyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 301666-34-2P 301666-37-5P 301667-04-9P  
 301667-05-0P 301667-31-2P 301667-32-3P  
 301668-00-8P 301668-02-0P 301668-04-2P  
 301668-05-3P 301668-07-5P 301668-10-0P  
 301668-13-3P 301668-16-6P 301668-17-7P  
 301668-20-2P 301668-21-3P 301668-22-4P  
 301668-29-1P 301668-30-4P 301668-32-6P  
 301668-33-7P 301668-50-8P 301668-51-9P  
 301668-53-1P 301668-55-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP. (Preparation); RACT (Reactant or reagent)

(prepn. of nitrogen-contg. heterocyclic compds. and benzamide compds.  
as hypolipidemics and antiarteriosclerotics and inhibitors of  
apolipoprotein B-contg. lipoproteins and biosynthesis of triglycerides)


RN 301666-34-2 CAPLUS

CN Benzoic acid, 3-[4-[4-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301666-37-5 CAPLUS

CN Benzoic acid, 4-[4-[4-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301667-04-9 CAPLUS  
 CN 3-Pyridinecarboxylic acid, 6-[4-[4-[9-[[ (2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 301667-05-0 CAPLUS  
 CN 3-Pyridinecarboxylic acid, 6-[4-[4-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 301667-31-2 CAPLUS  
 CN 9H-Fluorene-9-carboxylic acid, 9-[2-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A





RN 301667-32-3 CAPLUS


CN 9H-Fluorene-9-carboxylic acid, 9-[2-[4-(2-cyclohexyl-2,3-dihydro-3-oxo-1H-isoindol-5-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 301668-00-8 CAPLUS

CN Benzoic acid, 4-[4-[3-[9-[[2,2,2-trifluoroethyl]amino]carbonyl]-9H-fluoren-9-yl]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-02-0 CAPLUS  
 CN Benzoic acid, 4-[4-[4-[9-[[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-xanthen-9-yl]butyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 301668-05-3 CAPLUS

CN Benzoic acid, 2-chloro-4-[4-[4-[9-[[ (2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-07-5 CAPLUS

CN Benzoic acid, 4-[4-[4-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-10-0 CAPLUS  
 CN Benzoic acid, 2-methyl-3-[4-[3-[9-[[ (2,2,2-trifluoroethyl)amino]carbonyl]-9H-xanthen-9-yl]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-13-3 CAPLUS  
 CN Benzoic acid, 4-[4-[5-[9-[[ (2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]pentyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 301668-16-6 CAPLUS

CN Benzoic acid, 4-[4-[4-[9-[[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-2-(trifluoromethyl)-, ethyl ester (9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-17-7 CAPLUS

CN Benzoic acid, 4-[4-[4-[9-[[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-20-2 CAPLUS

CN Benzoic acid, 2-fluoro-4-[4-[4-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-21-3 CAPLUS

CN Benzoic acid, 2-fluoro-4-[4-[4-[9-[[ (2,2,2-trifluoroethyl) amino] carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 301668-22-4 CAPLUS

CN 9H-Fluorene-9-carboxamide, 9-[4-[4-[4-[[ (phenylmethyl) [(tetrahydro-2-furanyl)methyl] amino] carbonyl]phenyl]-1-piperazinyl]butyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-29-1 CAPLUS  
 CN Benzoic acid, 2-methyl-5-[4-[3-[9-[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-30-4 CAPLUS

CN Benzoic acid, 2-methyl-5-[4-[3-[9-[[ (2,2,2-trifluoroethyl) amino] carbonyl]-9H-fluoren-9-yl]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-32-6 CAPLUS  
 CN Benzoic acid, 3-[4-[3-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-33-7 CAPLUS  
 CN Benzoic acid, 3-[4-[3-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 301668-50-8 CAPLUS


CN Benzoic acid, 2-methyl-3-[4-[4-[9-[[ (2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 301668-51-9 CAPLUS

CN Benzoic acid, 2-methyl-3-[4-[4-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]butyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 301668-53-1 CAPLUS

CN Benzoic acid, 2-methyl-3-[4-[4-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-xanthen-9-yl]butyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 301668-55-3 CAPLUS  
 CN Benzoic acid, 2-methyl-3-[4-[3-[9-[[ (2,2,2-trifluoroethyl) amino] carbonyl]-9H-fluoren-9-yl]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 27      THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1969:449649 CAPLUS  
 DN 71:49649  
 TI Butynyl xanthenes and fluorenes  
 IN Cavalla, John F.; Simpson, Roy; White, Alan Chapman  
 PA Wyeth, John, and Brother Ltd.  
 SO Brit., 8 pp.  
 CODEN: BRXXAA  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1147832		19690410	GB	19670213
GI	For diagram(s), see printed CA Issue.				
AB	<p>The title compds. exhibiting antiulcer, central nervous system depressant, and antiinflammatory activity in exptl. animals were prepd. from propynyl derivs. by the Mannich reaction. To a soln. of 5.5 g. I (R1 = CO2Me, R2 = H) and 17.6 g. Et2NH in 50 ml. dioxane was added 30 mg. CuCl and 0.72 g. paraformaldehyde (Ia) and the mixt. heated on a steam bath for 1 hr. The solvent was evapd., and the residue in aq. HCl was extd. with CH2Cl2 to give 3.7 g. fluorene deriv. I (R2 = CH2NR2) (II).HCl (R1 = CO2Me, R = Et) (III), m. 193-4.5.degree.. The base from 3 g. III was refluxed with 3 ml. MeI in 20 ml. Me2CO for 2 hrs. to give 3.38 g. of the corresponding methiodide, m. 132-3.degree. (Me2CO-Et2O). The following II (R1 = CO2Me) were similarly prepd. (NR2, m.p. of hydrochloride, and m.p. of methiodide given): morpholino, 188-9.5.degree., 200-2.degree.; PhCH2NMe, 180-1.degree., 193-5.degree.; 1-pyrrolidinyl, 206-7.degree., 190-2.degree.; iso-Pr2N, 196-8.degree., 158-9.degree.; 4-phenyl-1-piperazinyl, 183-4.degree., -; HOCH2CH2NMe, 167.9.degree., -; morpholino (IV), 190-2.degree., -. A soln. of 18 g. IV base in 100 ml. tetrahydrofuran (THF) was added slowly to a stirred suspension of 6.4 g. LiAlH4 in 50 ml. THF and the mixt. refluxed 3 hrs. to give 14.7 g. II. HCl (R1 = CH2OH, NR2 = morpholino), m. 239-40.degree. (iso-PrOH-Et2O). Similarly prepd. were II.HCl (R1 = CH2OH, R = iso-Pr), m. 242-4.degree., and II.HCl (R1 = CH2OH, R = Et). 0.5 H2O, m. 149-51.degree.. A mixt. of 12 g. Me 9-xanthenecarboxylate, 2.4 g. NaH (50% in oil), and 50 ml. HCONMe2 (DMF) was stirred at room temp. for 30 min., treated dropwise with 6 g. CH.tplbond.CCH2Br in 50 ml. DMF and stirred for 1 hr. to give 11.6 g. Me 9-(2-propynyl)-9-xanthenecarboxylate (V), m. 115-17.degree.. Refluxing a mixt. 5 g. V, 0.6 g. Ia, 1.74 g. morpholine, and CuCl in dioxane for 4 hrs. gave 5.69 g. VI.HCl (R1 = CO2Me, NR2 = morpholino), m. 189-90.degree. (iso-PrOH-Et2O). Similarly prepd. were VI.HCl (R1 = CO2Me, R = iso-Pr) (VII), m. 209-10.degree., VI.HCl (R1 = CO2Me, R = Et), m. 198-9.degree., and VI.HCl (R1 = CO2Me, R = PhCH2NMe), m. 178-9.degree.. The methiodide prepd. from VII base m. 157-8.degree. (MeOHEt2O). Allowing a soln. of 1.9 g. III and 20 ml. 33% methanolic MeNH2 to stand for 2 days, evapg., and converting the resulting base to the hydrochloride gave II.HCl (R1 = CONHMe, R = Et), m. 208-9.degree.. Treatment of III with methanolic NH3 for 2 weeks at room temp. gave II.HCl (R1 = CONH2, R = Et), m. 239-40.degree.. II.HCl (R1 = CONHMe, R = iso-Pr), m. 206-8.degree., was similarly prepd. Heating VII with excess 33% ethanolic MeNH2 in an autoclave at 100.degree. for 24 hrs. gave VI (R1 = CONHMe, R = iso-Pr), m. 108-9.degree. (petroleum ether), while with methanolic NH3 at 150.degree. for 4 days, VII gave VI (R1 = CONH2, R = iso-Pr), m. 97-8.degree. (petroleum ether). To a suspension of NaNH2 in 900 ml. liq. NH3 was added 67.8 g. 9-xanthenecarboxylic acid. To the red soln. 1 l. Et2O was added, the mixt. stirred 1.5 hrs. and treated with 51.4 g. CH.tplbond.CCH2Br to</p>				



give 52.7 g. 9-(2-propynyl)-9-xanthenecarboxylic acid (VIII), m. 199-202.degree. (C<sub>6</sub>H<sub>6</sub>). The acid chloride (IX) of VIII was prepd. by refluxing 9.05 g. VIII with 15 ml. SOCl<sub>2</sub> in 78 ml. C<sub>6</sub>H<sub>6</sub> for 1.5 hrs. Re-fluxing IX with 60 ml. 25% ethanolic Me<sub>2</sub>NH gave 6.72 g. N,N-dimethyl-9-(2-propynyl)-9-xanthenecarboxamide (X), m. 175-8.degree.. Reacting 2.91 g. X, 0.88 g. Et<sub>2</sub>NH, 0.36 g. Ia, and 50 mg. CuCl in dioxane gave 2.56 g. VI.HCl.0.5 H<sub>2</sub>O (R<sub>1</sub> = CONMe<sub>2</sub>, R = Et) m. 183-7.degree..

IT **23055-59-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 23055-59-6 CAPLUS

CN Fluorene-9-carboxylic acid, 9-[4-(4-phenyl-1-piperazinyl)-2-butynyl]-, methyl ester, hydrochloride (8CI) (CA INDEX NAME)



● HCl

10/089024

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.98	182.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

FILE 'CAOLD' ENTERED AT 17:46:48 ON 02 OCT 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 13

L5 0 L3

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	183.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.60

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 17:46:58 ON 02 OCT 2003